Formosa Pharmaceuticals is a preclinical and clinical stage biopharmaceutical company with focus in the therapeutic areas of ophthalmology, oncology, and anti-infectives.
News Highlight
- Formosa Pharmaceuticals announce registration on Emerging Stock Board of the Taipei Stock Exchange (TPEx)
- Formosa Pharmaceuticals and China Grand Pharmaceutical and Healthcare Holdings Limited enter into licensing agreement for APP13007
- Formosa Pharmaceuticals completes USD $21.1 million fundraising and increase in cash capital
Formosa Pharma is developing a unique pipeline consisting of risk-diverse development modes, including 505(b)(2), biosimilars, and NCEs. Our proprietary APNT nanoparticle formulation platform, from which lead program APP13007 is derived, is available for application to drug candidates in need of improving pharmacokinetics and bioavailability.
